Xeris Biopharma Holdings, Inc.
XERS
$5.48
-$0.25-4.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.72% | 42.05% | 35.62% | 29.88% | 23.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.72% | 42.05% | 35.62% | 29.88% | 23.89% |
| Cost of Revenue | 15.58% | 17.68% | 47.96% | 35.13% | 28.58% |
| Gross Profit | 49.95% | 47.63% | 33.21% | 28.79% | 22.89% |
| SG&A Expenses | 11.56% | 8.76% | 13.24% | 12.10% | 11.90% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | -0.01% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.77% | 10.24% | 17.04% | 13.27% | 13.85% |
| Operating Income | 173.99% | 121.70% | 73.59% | 50.00% | 23.55% |
| Income Before Tax | 100.97% | 76.16% | 40.21% | 27.08% | 10.08% |
| Income Tax Expenses | -- | 100.00% | -789.63% | -173.35% | -81.59% |
| Earnings from Continuing Operations | 101.01% | 75.22% | 46.28% | 30.01% | 11.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 101.01% | 75.22% | 46.28% | 30.01% | 11.92% |
| EBIT | 173.99% | 121.70% | 73.59% | 50.00% | 23.55% |
| EBITDA | 271.73% | 166.35% | 109.12% | 68.08% | 31.89% |
| EPS Basic | 99.47% | 76.50% | 49.57% | 35.13% | 16.87% |
| Normalized Basic EPS | 99.48% | 78.65% | 44.61% | 32.71% | 15.84% |
| EPS Diluted | 98.84% | 76.66% | 48.53% | 34.19% | 15.89% |
| Normalized Diluted EPS | 98.13% | 78.59% | 44.61% | 32.71% | 15.84% |
| Average Basic Shares Outstanding | 9.30% | 8.45% | 7.95% | 8.09% | 6.59% |
| Average Diluted Shares Outstanding | 14.08% | 10.87% | 7.95% | 8.09% | 6.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |